Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Account Payables: 2012-2024

Historic Change in Account Payables for Ani Pharmaceuticals (ANIP) over the last 13 years, with Dec 2024 value amounting to $479,000.

  • Ani Pharmaceuticals' Change in Account Payables rose 547.09% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year increase of 54.46%. This contributed to the annual value of $479,000 for FY2024, which is 93.66% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Change in Account Payables stood at $479,000 for FY2024, which was down 93.66% from $7.6 million recorded in FY2023.
  • Over the past 5 years, Ani Pharmaceuticals' Change in Account Payables peaked at $10.2 million during FY2021, and registered a low of -$2.3 million during FY2020.
  • Moreover, its 3-year median value for Change in Account Payables was $5.0 million (2022), whereas its average is $4.4 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Change in Account Payables tumbled by 145.52% in 2020, and later soared by 543.16% in 2021.
  • Ani Pharmaceuticals' Change in Account Payables (Yearly) stood at -$2.3 million in 2020, then spiked by 543.16% to $10.2 million in 2021, then slumped by 50.44% to $5.0 million in 2022, then soared by 49.90% to $7.6 million in 2023, then slumped by 93.66% to $479,000 in 2024.